T. Rowe Price Associates, Inc. filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,501,189 shares of Q32 Bio Inc common stock as of September 30, 2026.
Key Highlights
- Total beneficial ownership: T. Rowe Price Associates, Inc. reported aggregate beneficial ownership of 1,501,189 shares of Q32 Bio Inc common stock.
- Percent of class: The 1,501,189 shares represent 5.0% of the outstanding class, according to the filing.
- Sole voting and dispositive power: T. Rowe Price Associates, Inc. reported sole voting power and sole dispositive power over all 1,501,189 shares, with no shared voting or dispositive power.
- T. Rowe Price Health Sciences Fund interest: The filing identifies T. Rowe Price Health Sciences Fund as holding 1,170,394 of the reported shares, representing 9.5% of the class, with the right to receive dividends or proceeds from the sale of those shares.
- Triggering event date: The date of event requiring the filing was September 30, 2026.
- Filer classification: T. Rowe Price Associates, Inc. is identified as an investment adviser (type "IA"), organized in Maryland, with its principal office at 1307 Point Street, Baltimore, MD 21231.
T. Rowe Price Associates Crosses 5% Threshold in Q32 Bio Common Stock
According to the Schedule 13G filed on November 16, 2026, T. Rowe Price Associates, Inc. disclosed that it beneficially owns 1,501,189 shares of common stock of Q32 Bio Inc (NASDAQ:QTTB), a company whose principal executive offices are located at 830 Winter Street, Waltham, MA. The filing was triggered by an event dated September 30, 2026, and was signed by Ellen York, Vice President of T. Rowe Price Associates, Inc.
The filing states that T. Rowe Price Associates, Inc. holds sole voting power and sole dispositive power over all 1,501,189 shares, with zero shares subject to shared voting or shared dispositive power. The filing further discloses that T. Rowe Price Health Sciences Fund, for which T. Rowe Price Associates, Inc. serves as investment adviser, holds 1,170,394 of those shares and has the right to receive, or the power to direct the receipt of, dividends and sale proceeds attributable to those shares. That sub-holding represents 9.5% of the class, as stated in the filing.
The filing notes that "Price Associates does not serve as custodian of the assets of any of its clients," and that "the ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser." Additionally, T. Rowe Price Associates, Inc. included a certification stating the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
What Was Disclosed
T. Rowe Price Associates, Inc. filed a Schedule 13G reporting a 5.0% beneficial ownership position of 1,501,189 shares in Q32 Bio Inc common stock as of September 30, 2026, with T. Rowe Price Health Sciences Fund identified as holding 1,170,394 of those shares.



Please wait processing your request...